Equities

Molecular Templates Inc

MTEM:NAQ

Molecular Templates Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.31
  • Today's Change-0.095 / -6.79%
  • Shares traded56.42k
  • 1 Year change-82.60%
  • Beta1.2050
Data delayed at least 15 minutes, as of Jun 14 2024 20:54 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. The Company’s proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).

  • Revenue in USD (TTM)31.76m
  • Net income in USD-18.40m
  • Incorporated2001
  • Employees62.00
  • Location
    Molecular Templates Inc9301 Amberglen Blvd Ste 100AUSTIN 78729-1153United StatesUSA
  • Phone+1 (512) 896-1555
  • Fax+1 (302) 655-5049
  • Websitehttps://mtem.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
BioNexus Gene Lab Corp9.78m-2.66m7.81m30.00--0.8357--0.7989-0.14-0.140.6510.52891.018.555.80---27.53-3.83-33.16-5.0213.5614.55-27.25-3.043.98-162.450.00---10.60115.07-638.56--30.40--
Transcode Therapeutics Inc0.00-17.06m7.95m10.00--1.52-----206.36-206.360.000.78930.00----0.00-264.82-133.14-721.90-181.26-----------148.050.00-------5.59------
Allarity Therapeutics Inc0.00-20.94m8.01m5.00---------599.34-599.340.00-18.880.00----0.00-100.46--------------------------3.02------
Psyence Biomedical Ltd0.001.52m8.08m------5.33---0.0442-0.04420.00-0.39790.00------1.13--1.20-----------------------2.63------
Universe Pharmaceuticals Inc32.31m-6.16m8.09m225.00--0.2036--0.2505-1.70-1.708.9110.910.57277.932.50143,594.40-10.925.31-14.347.0731.9346.26-19.086.252.43-28.050.12180.00-19.522.5329.46---21.17--
Enzolytics Inc0.00-119.19k8.29m2.00---------0.106-0.1060.00-1.040.00-------369.52-----------------4.30-----100.00---9.35------
Nymox Pharmaceutical Corp0.00-4.87m8.39m3.00---------0.0536-0.05360.00-0.02040.00-------255.75-264.40---464.48-------13,001.67---42.44--------47.55------
Molecular Templates Inc31.76m-18.40m8.59m62.00--1.19--0.2705-4.36-4.365.981.090.6014--19.55512,306.40-34.83-51.78-54.80-73.14-----57.92-228.33---52.110.00--190.1033.9691.24---48.87--
Protext Mobility Inc750.00-2.21m8.79m4.00------11,721.63-0.4692-0.46920.00001-0.01020.0405-------9,400.97-1,587.94----86.67-530.19-232,392.00-17,498.830.0002-1.36-----93.98-63.0927.35------
Lotus Pharmaceuticals Inc70.79m1.72m8.89m233.000.05960.00092.300.12560.05530.05532.563.580.632137.2717.85303,836.901.5522.841.7126.4035.1041.622.4519.930.442830.800.05160.0028.7131.70-12.2251.1170.48--
Bon Natural Life Ltd29.52m4.60m9.25m96.000.46690.07711.680.31344.994.9932.1030.230.704515.275.19307,524.6010.8614.0413.6920.6829.9430.0015.4217.622.4130.540.09550.00-1.2922.32-26.3283.09-6.70--
ABVC Biopharma Inc25.37k-12.62m9.32m16.00--1.18--367.43-2.37-2.370.00430.72840.002--0.06731,585.63-103.15-103.38-189.31-231.54-854.2076.25-51,218.29-2,019.89---3.190.1853---84.2885.3935.97------
Pacific Software Inc0.00-77.46k9.36m0.00--0.3008-----0.1832-0.18320.000.76460.00-------26.19-620.48-66.38-------------6.290.00-------13.29------
Data as of Jun 14 2024. Currency figures normalised to Molecular Templates Inc's reporting currency: US Dollar USD

Institutional shareholders

48.92%Per cent of shares held by top holders
HolderShares% Held
Bellevue Asset Management AGas of 31 Mar 20241.03m19.16%
BVF Partners LPas of 31 Mar 2024522.24k9.72%
SilverArc Capital Management LLCas of 31 Mar 2024354.61k6.60%
Adage Capital Management LPas of 31 Mar 2024257.20k4.79%
Caxton Corp.as of 31 Mar 2024136.87k2.55%
The Vanguard Group, Inc.as of 31 Mar 2024125.61k2.34%
Monashee Investment Management LLCas of 31 Mar 2024105.49k1.96%
BlackRock Fund Advisorsas of 31 Mar 202439.64k0.74%
Geode Capital Management LLCas of 31 Mar 202437.43k0.70%
Renaissance Technologies LLCas of 31 Mar 202420.05k0.37%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.